A Shot Every Three Months Wins Approval in Myasthenia Gravis

The FDA approved Regeneron's cemdisiran, the first siRNA therapy in generalized myasthenia gravis, on data where partial complement blockade outscored near-complete blockade. Quarterly dosing is the selling point; the boxed warning is the cost.

Share
A molecular rendering of a small interfering RNA molecule loaded into a cell's gene-silencing complex, illustrating how cemdisiran reduces complement C5 production

Regeneron's Livsayis (cemdisiran) won FDA approval on 18 November 2026 for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, and it carries two distinctions no other drug in the field can claim: the first small interfering RNA therapy approved in gMG, and the only approved gMG treatment given as a subcutaneous injection four times a year. Cemdisiran works by degrading the mRNA that encodes complement C5, lowering circulating C5 and limiting terminal complement activation. For Regeneron, it is also a first approved siRNA therapy and a first approved neurology medicine.

The dosing schedule alone would make Livsayis noteworthy. But the more interesting finding sits inside the Phase 3 data, and it complicates an assumption that has guided complement-directed drug development in this disease.

Partial Blockade Outscored Near-Complete Blockade in One Trial

The pivotal NIMBLE trial randomized 284 patients across 86 centres in 13 countries to a 24-week double-blind period. On the primary endpoint, the MG-ADL score at week 24, cemdisiran monotherapy (600 mg every 12 weeks, n=64) produced a 4.5-point improvement versus 2.2 points on placebo (n=59), a placebo-adjusted difference of 2.3 points (95% CI -3.6 to -1.0; p=0.0005). Responders with at least a 3-point improvement reached 76.6% versus 44.1% (p<0.001). On the key secondary endpoint, Quantitative Myasthenia Gravis, the difference was 2.8 points (p=0.0015), with 48.4% versus 19.0% achieving at least a 5-point improvement. Benefit appeared as early as two weeks and held through 24 weeks without any indication of waning.

Here is the wrinkle. Monotherapy was associated with about 74% inhibition of complement activity. A separate combination arm, pairing cemdisiran 200 mg with the C5 antibody pozelimab 200 mg every 4 weeks, pushed inhibition to nearly 99%. That arm produced a smaller placebo-adjusted MG-ADL difference of 1.7 points (p=0.0086), numerically worse than monotherapy. Regeneron's own release said monotherapy was numerically better across the gMG endpoints and framed the result as evidence that robust efficacy is possible without complete complement blockade. The limits matter: the trial was not designed to test one arm against the other, and the cross-arm comparison was not the basis of approval. Still, the pattern runs against the premise behind the C5 inhibitors already on the market, which aim for near-total blockade.

The safety trade is familiar but real

The prescribing information carries a Boxed Warning for serious meningococcal infections, along with warnings for other serious infections, consistent with other C5-reducing medicines. Livsayis is available only through a Risk Evaluation and Mitigation Strategy program, and patients must complete meningococcal vaccination at least two weeks before a first dose. The trial data were clean. In the Lancet report, no serious or meningococcal infections occurred in the cemdisiran group, and adverse events occurred in 69% of cemdisiran patients versus 77% of placebo patients. The most common adverse reactions were injection site reactions, viral infections, and urinary tract infections.

The market it enters

Livsayis lands in a field where argenx's Vyvgart already dominates. Vyvgart, the first FcRn blocker approved in gMG in 2021, lowers circulating IgG antibodies rather than blocking complement. It is given in IV infusion cycles, and since 2023 a subcutaneous version can be injected at home. argenx describes it as the first and only approved treatment for all adult patients living with gMG, and reported $1.7 billion in global product net sales for the third quarter of 2026, up 54% year over year. Ultomiris, AstraZeneca's ravulizumab, approved for anti-AChR-positive gMG in April 2022, is dosed intravenously every eight weeks with what the company calls immediate, complete and sustained complement inhibition; its CHAMPION-MG trial enrolled 175 patients over 26 weeks. Against those profiles, Livsayis offers the longest interval between doses among approved gMG therapies, according to Regeneron, and a narrower label limited to anti-AChR antibody-positive adults. Roughly 85,000 people in the US have myasthenia gravis, per the company.

Alnylam, which discovered cemdisiran, will receive a $25 million payment for the approval plus tiered, double-digit royalties of up to 15% on global net sales. Livsayis is the seventh Alnylam-discovered RNAi therapeutic approved in under nine years. A European Union submission is under review with a decision anticipated in the second half of 2027, and submissions are planned in additional markets including Japan.

The question the approval leaves open is scientific more than commercial. If partial complement inhibition can match near-complete blockade in the same trial, then the field's assumption that more blockade means more benefit deserves a re-examination, and the next generation of complement programs will be designed with NIMBLE in mind.

BioReview, In your Inbox

Get our in depth reports sent directly to your inbox. Unsubscribe anytime.